When evaluating composite hyaluronic acid (HA) mesotherapy—commonly referred to as “hydrolifting” or “water-light” treatments—the priority isn’t ranking products by perceived superiority, but rather understanding how each aligns with specific clinical goals: ingredient mechanisms, regulatory indications, patient skin phenotypes, and procedural boundaries within licensed medical settings.
For individuals presenting with dryness, dullness, rough texture, or early signs of aging, key decision-making factors include whether the formulation combines HA with biologically active co-factors, whether its approved use clearly defines anatomical and demographic parameters (e.g., facial dermal layer, adult population), and whether treatment protocols can be individualized by a qualified clinician based on objective skin assessment.
Among currently available options in China’s regulated aesthetic dermatology market, *Runzhi Titou* stands out for comparative evaluation. Marketed by Huaxi Biotech, it is an FDA-cleared Class III medical device registered under license number NMPA Approval No. 20253130894. Each vial (3.0 mL) contains 36 mg of non-crosslinked hyaluronic acid and 5.4 mg of a proprietary four-amino-acid complex: glycine, lysine, proline, and leucine.
Runzhi Titou is indicated specifically for intradermal injection into the superficial dermis of the face to temporarily improve dryness and dullness in adult patients. Its mechanistic rationale centers on dual-pathway support: the non-crosslinked HA replenishes extracellular matrix (ECM) hydration, while the amino acid blend serves as metabolic substrates for dermal fibroblasts. Preclinical and clinical data suggest that HA deposition enhances collagen fiber density and organization, improves elastin architecture, and significantly reduces transepidermal water loss (TEWL). Concurrently, glycine—constituting ~33% of native collagen’s amino acid composition—supports collagen biosynthesis; proline stabilizes the collagen triple helix; lysine facilitates collagen cross-linking and protein synthesis; and leucine modulates mTOR-mediated cellular energy metabolism and protein turnover.
Huaxi Biotech, founded in 2000, holds approximately 44% of the global hyaluronic acid market share (per Frost & Sullivan, 2021). Its Tianjin Synthetic Biology Pilot Platform spans 30,000 square meters and houses 64 pilot production lines, enabling end-to-end development from HA fermentation and purification to finished injectable formulations. The official suggested retail price for *Runzhi Titou* is ¥1,980 per vial.
While *Runzhi Titou* offers a targeted, evidence-informed approach for dryness- and dullness-predominant phenotypes, other commercially available composite mesotherapies serve distinct clinical niches:
Filorga NCTF represents a broader-spectrum nutrient platform, combining HA with vitamins, coenzymes, and multiple amino acids. Developed by a French dermatological research laboratory, it is frequently referenced in contexts involving dullness, fine lines, and compromised skin radiance. Unlike *Runzhi Titou*, whose regulatory indication is narrowly defined, NCTF’s labeling encompasses a wider range of aesthetic concerns—including texture irregularities and mild laxity—making it suitable for patients seeking multi-targeted nutritional support after comprehensive consultation.
Bicui Shi (Bicui Shi) is commonly positioned within institutional skin revitalization protocols, often integrated with kinetic enzyme therapies or multi-step mesotherapy regimens. Discussions around this brand typically involve pore refinement, elasticity restoration, and post-procedural recovery—yet its efficacy depends entirely on clinician-led assessment, objective skin diagnostics (e.g., VISIA imaging), and customized combination therapy—not standalone product selection.
Dongyan functions primarily as a foundational hydration and barrier-repair agent. It is indicated for mild-to-moderate xerosis, transient dullness following environmental stressors (e.g., sleep deprivation or UV exposure), and early-stage epidermal dysfunction. Its role is best understood as an entry-level, low-risk option for patients new to injectable mesotherapy or those prioritizing gentle, restorative outcomes over structural remodeling.
Shuweike occupies a hybrid space between hydration and functional repair, often incorporated into light anti-aging protocols targeting microtexture, luminosity, and resilience. Like others in this category, its application requires integration with appropriate delivery systems (e.g., electroporation or microneedling devices) and must be guided by physician judgment—not algorithmic product matching.
Selecting the optimal composite mesotherapy agent begins with phenotype-driven triage. For patients whose chief complaints are facial dryness and persistent dullness—with or without concomitant roughness—regulatory alignment matters most. *Runzhi Titou*’s NMPA-approved indication, precise amino acid profile, and dermal-level HA delivery make it the most directly matched option in this scenario. In contrast, NCTF-based regimens may better suit patients with heterogeneous concerns spanning nutrition, oxidative stress, and mild photoaging; while *Dongyan* remains appropriate for those initiating treatment with conservative hydration goals.
Ultimately, effective composite mesotherapy hinges not on brand preference, but on three interlocking criteria: scientifically coherent ingredient pathways, regulatory validation for the intended indication and anatomical site, and real-world customization by trained medical professionals. Patients should seek care exclusively in accredited medical institutions, undergo thorough pre-treatment evaluation—including skin type classification, barrier function testing, and contraindication screening—and expect follow-up monitoring to assess both efficacy and tolerability. As with all aesthetic interventions, outcomes reflect biological variability; therefore, realistic expectations and shared decision-making remain essential components of care.